Here are more of the details.
VANCOUVER, British Columbia, Sept. 17 /PRNewswire/ -- Robert B. Rieveley,
President of Biotech Holdings Ltd. ("Biotech") (OTC Bulletin Board: BIOHF)
(Alberta: BIO), today announced a summary of results of Biotech's recently
completed clinical trial in Brazil.
"The purpose of the clinical trial," Mr. Rieveley said, "was to provide
supplementary information for a regulatory application for approval of our
diabetes drug, DIAB II, in Brazil as a prescription treatment for Type II or
Adult-Onset Diabetes."
Mr. Rieveley noted that the trial was carried out by one of the largest
independent contract research laboratories in Brazil, working with Brazilian
doctors specializing in diabetes. Trial design was reviewed by Biotech and by
Biobras S.A ("Biobras"). Biobras, Biotech's licensee in Brazil, is the fourth
largest insulin manufacturer in the world and formerly a subsidiary of
Eli Lilly.
The study evaluated the effect on diagnosed Type II diabetics of replacing
their usual diabetes medication with DIAB II. On enrolling in the study,
patients continued their normal activity and eating patterns while patients'
drug regimens were switched to DIAB II twice daily.
Parameters measured included plasma insulin, HDL and LDL cholesterol,
triglycerides and glycosylated hemoglobin (Hb A1c), a key indicator of
diabetes control. Toxicity monitoring and monitoring of weight, blood
pressure, heart rate and temperature was carried out during multiple
laboratory visits during a period of eight weeks.
During DIAB II treatment, no hepatic or other organ toxicity was detected
in laboratory tests and no adverse clinical events were reported. Plasma
insulin, HDL/LDL ratio and triglycerides were controlled equally well with
DIAB II treatment as on the patients' accustomed medication. The critical
Hb A1c measurement showed reduced levels during the course of the study, to an
average of 5.85%, indicating excellent diabetic control. It was noted that
patients on average also experienced weight loss during the course of the
trial.
"Results of the Brazil trial," Mr. Rieveley pointed out, "are in line with
earlier results from China, where DIAB II is sold as a prescription drug.
With a demonstrated lack of the toxicity that characterizes some
insulin-sensitizing drugs and with demonstrated efficacy, we believe that
DIAB II should become the market leader for insulin-sensitizing drugs wherever
introduced."
DIAB II, an oral diabetes drug, is an insulin-receptor sensitizer, a new
class of drugs for controlling the chronically high blood sugar level that
typifies diabetes. DIAB II works by improving the patient's ability to
utilize both endogenous and injected insulin, the hormone that regulates blood
sugar levels. Type II Diabetes affects more than 15 million people in the
United States, over 20 million in Latin America and over 150 million people
worldwide.
Biotech Holdings is located in Vancouver, British Columbia, Canada with
its plant in Richmond, BC. Biotech Holdings' shares trade on the Over the
Counter Bulletin Board (symbol: BIOHF) and on the Alberta Stock Exchange
(symbol: BIO).
For inquiries, contact Austin Rand at Biotech Holdings Ltd.,
1-888-216-1111 (toll-free) 8 a.m. to 5 p.m. Pacific time, or by e-mail at
biotech@direct.ca. For further information, please visit Biotech's website at
biotechltd.com .
This release contains forward-looking statements within the meaning of
Section 21 E of the Securities and Exchange Act of 1934, as amended. Although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, actual results may differ for reasons that include
but are not limited to political and economic conditions in the countries in
which the Company does or intends to do business, regulatory action, product
pricing and competitive market conditions. These forward-looking statements
represent the Company's judgement at the date of this release and any changes
in assumptions or external factors could produce significantly different
results.
SOURCE Biotech Holdings Ltd.
Web Site: biotechltd.com
(Today's News) (Company News On-Call) (Feature News) (Automotive)
(Entertainment) (Health/Biotech)(Technology) (Financial) (Energy)
(Washington and the World) (Money Talks) (About PRN)(Ask PRN) (Links) (PRN Events) |
